Pacira Pharmaceuticals (Nasdaq: PCRX) is expected to report Q2 earnings on Aug. 9. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pacira Pharmaceuticals' revenues will increase 141.1% and EPS will remain in the red.

The average estimate for revenue is $8.8 million. On the bottom line, the average EPS estimate is -$0.52.

Revenue details
Last quarter, Pacira Pharmaceuticals chalked up revenue of $7.8 million. GAAP reported sales were much higher than the prior-year quarter's $3.9 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, EPS came in at -$0.47. GAAP EPS were -$0.47 for Q1 versus -$0.98 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 16.8%, 1,170 basis points better than the prior-year quarter. Operating margin was -142.7%, 4,170 basis points better than the prior-year quarter. Net margin was -152.4%, 10,060 basis points better than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $41.0 million. The average EPS estimate is -$1.54.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 17 members out of 26 rating the stock outperform, and nine members rating it underperform. Among nine CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give Pacira Pharmaceuticals a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $16.20.

Over the decades, small-cap stocks, like Pacira Pharmaceuticals have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.